SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Clinical trial NCT00215540 · TERMINATED

Trial details

NCT number: NCT00215540
Sponsor: Windtree Therapeutics
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Respiratory Distress Syndrome, Newborn Premature Birth Bronchopulmonary Dysplasia

Start date: 2005-02-01
Primary completion: 2006-07-01
Enrollment: 136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.